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The initial requirement for the emergence of CMV-speciﬁc CD8
1 T cells is poorly under-
stood. Mice deﬁcient in the cosignaling TNF superfamily member, 4-1BB, surprisingly
developed exaggerated early CD8
1 T-cell responses to mouse CMV (MCMV). CD8
1
T cells directed against acute MCMV epitopes were enhanced, demonstrating that 4-1BB
naturally antagonizes these primary populations. Paradoxically, 4-1BB-deﬁcient mice
displayed reduced accumulation of memory CD8
1 T cells that expand during chronic/
latent infection. Importantly, the canonical TNF-related ligand, 4-1BBL, promoted the
accumulation of these memory CD8
1 T cells, whereas suppression of acute CD8
1 T cells
was independent of 4-1BBL. These data highlight the dual nature of the 4-1BB/4-1BBL
system in mediating both stimulatory and inhibitory cosignaling activities during the
generation of anti-MCMV immunity.
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Introduction
CD8
1 T cells are critical mediators of immunity to CMV infection.
Virus reactivation in immune-compromised individuals correlates
with defective CD8
1 T-cell responses [1, 2] and transfer of
human CMV-speciﬁc CD8
1 T cells limits viremia in immune-
suppressed recipients [3, 4]. Interestingly, in healthy aging
individuals, human CMV-speciﬁc CD8
1 T cells expand to high
numbers, comprising over 10% of the entire CD8
1 repertoire
[5, 6]. Although these T cells maintain their proliferative and
cytolytic capacity [7], this enhanced frequency that dominates
the global T-cell repertoire is associated with impaired T-cell
responsiveness to heterologous antigens [8]. As human CMV may
impinge on immunity to other pathogens, understanding how
such virus-speciﬁc CD8
1 T-cell populations arise and are
controlled may lead to new strategies to modulate these cells
for the design of immune therapeutic and vaccination strategies.
However, little is known regarding the immunological factors
that determine the expansion and/or survival of distinct CMV-
reactive T-cell subsets in vivo.
Due to the species-speciﬁc nature of HCMV replication, mouse
CMV (MCMV) represents a useful system for modeling the
pathogenesis and immunity of CMV infection in vivo. Similar to
human CMV, MCMV persists in its natural host, following acute
infection and establishes latency [9]. CD8
1 T-cell responses
elicited by MCMV infection are well characterized and consist of
cellular expansion and contraction of deﬁned epitope-speciﬁc
populations during acute infection, followed by an accumulation
of distinct populations of ‘‘inﬂationary’’ CD8
1 T cells thought to
be representative of those observed in human CMV-infected
individuals [10–13]. Transfer of CD8
1 T cells from immune
donors also reduces MCMV replication in immune-suppressed
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1 T cells limit MCMV reactivation
during latency [15].
4-1BB (CD137, TNFRSF9) is a member of the TNF receptor
superfamily that is highly expressed by T cells following activa-
tion [16]. Its known TNF-related ligand, 4-1BB ligand (4-1BBL,
CD137L and TNFSF9), is expressed by activated APC [17, 18].
Following ligation in vitro, 4-1BB delivers a positive stimulatory
signal to T cells promoting proliferation, survival and cytokine
production. Evidence from some models of viral infection also
suggests a critical role for the 4-1BB/4-1BBL pathway in modu-
lating virus-speciﬁc CD8
1 T-cell responses in vivo. Administration
of an agonist antibody to 4-1BB was shown to enhance cyto-
toxicity and broaden the CD8
1 T-cell repertoire during acute
inﬂuenza infection [19]. Additionally, endogenous 4-1BB/4-1BBL
interactions have been shown to act late, after normal develop-
ment of acute responses, to promote inﬂuenza-speciﬁc CD8
1
T-cell memory formation, and also participate in either the
maintenance and/or the reactivation of these persisting cells
[20, 21]. More recently, 4-1BBL
/ mice were found to generate
impaired functional CD8
1 T cells during latent mouse gamma-
herpesvirus-68 (MHV-68) infection although their numbers were
not affected [22].
Despite the plethora of evidence suggesting that the
4-1BB/4-1BBL pathway acts as a positive regulator of CD8
1
T-cell immunity, 4-1BB-deﬁcient mice displayed hyper-respon-
siveness to immunization with some model protein antigens [23],
and 4-1BB-deﬁcient CD8
1 T cells were found to expand to a
greater extent to an antigen delivered via adenovirus, even
when responding in vivo in a 4-1BB-sufﬁcient environment
[24]. Furthermore, exogenous stimulation of 4-1BB by
administering an agonist antibody at the time of LCMV infection
was shown to inhibit rather than promote the generation of
LCMV-speciﬁc CD8
1 T cells [25]. These contradictory observa-
tions highlight the need for a greater understanding of the role
that 4-1BB plays in the regulation of anti-viral CD8
1 T-cell
responses in vivo. In this study, we assessed the impact that 4-1BB
and 4-1BBL have on the initial generation of MCMV-speciﬁc
CD8
1 T cells.
Results and discussion
4-1BB limits CD8
1 T-cell accumulation during acute
MCMV infection
WT C57BL/6 (B6) and 4-1BB-deﬁcient mice were infected with
MCMV and virus-speciﬁc CD8
1 T-cell activity was measured, as
identiﬁed by IFN-g expression following ex vivo stimulation of
splenocytes with H-2
b-restricted peptides derived from either
M38, M45, M57 or m139 MCMV proteins. During MCMV
infection, the hierarchy of the CD8
1 T-cell response shifts from
an acute response predominated by cells recognizing M45, M57,
and, to a lesser extent, m139-derived peptides, to a persistent
response where m139 and M38-speciﬁc CD8
1 T cells are
immunodominant [26].
At day 7, the numbers of MCMV-speciﬁc CD8
1 T cells
responsive to M45 (Fig. 1A), M57 (Fig. 1B) and m139 (Fig. 1D)
were surprisingly elevated in the spleens (Fig. 1E) and lungs
(data not shown) of 4-1BB
/ mice; this was particularly evident
with M45 and M57 populations, and was also observed when
tetramers loaded with peptides of M45 (Fig. 1G) or m139 (data
not shown) were used to identify virus-speciﬁc CD8
1CD44
1
T cells. These observations directly correlate with our earlier
ﬁnding that 4-1BB-deﬁcient CD8
1 T cells expanded to a greater
extent to an antigen expressed in adenovirus [24]. Very low
numbers of M38-speciﬁc CD8
1 T cells were detected in both
groups of mice (Fig. 1C and E). Interestingly, and in contrast to
the infection data, increased accumulation of M45-speciﬁc CD8
1
T cells in 4-1BB
/ mice was not observed following peptide
immunization (Fig. 1H), suggesting that the inhibitory function
of 4-1BB is only apparent under particular conditions and that
MCMV infection promotes this activity.
Increased CD8
1 T-cell responses in MCMV-infected 4-1BB
/
mice were not accompanied by increased numbers of NK cells at 3
and 7 days post-infection (data not shown). On the contrary,
virus-speciﬁc splenic CD4
1 T cells were elevated in 4-1BB
/
mice 7 days post-infection (Fig. 1I). Importantly, however,
acute MCMV-speciﬁc CD8
1 T-cell responses are not dependent on
CD4
1 T cells [27, 28], implying that 4-1BB directly suppresses the
priming of acute MCMV-speciﬁc CD8
1 T-cell populations, rather
than acting indirectly by modulating CD4
1 T-cell activity. The
enhanced accumulation of MCMV-reactive CD8
1 T cells might
have been a consequence of modulating the viral load. However,
as described above, early splenic NK cell numbers were not
altered in the absence of 4-1BB, implying that early antiviral
protection should have been comparable in WT and
4-1BB
/ mice. Also, lysis of M45 peptide-loaded target cells was
equally efﬁcient following transfer into MCMV-infected WT and
4-1BB
/ mice (Fig. 1J) and, in accordance, viral burden in the
spleen (Fig. 1K) and salivary gland (Fig. 1L) was not signiﬁcantly
different between WT and 4-1BB
/ mice at day 7 post-infection.
These observations suggest that elevated numbers of MCMV-
reactive CD8
1 T cells were not a consequence of altered exposure
to viral antigens, and that a 2-fold increase in virus-speciﬁc
CD8
1 T-cell numbers does not reduce MCMV burden during
acute infection of 4-1BB
/ mice.
4-1BB promotes MCMV-speciﬁc CD8
1 T-cell memory
responses
Next, we studied CD8
1 T-cell responses at later times after
infection. The populations of acute M45- and M57-speciﬁc CD8
1
T cells contract rapidly after 7–8 days [26], and a deﬁciency in
4-1BB did not overtly abrogate this process. However, a small
increase in the numbers of these stable M45- and M57-speciﬁc
memory populations was observed 30 days post-infection in
the spleens (Fig. 1A, B and F) and lungs (data not shown) of
4-1BB
/ mice. Strikingly, and in contrast to the acute
phase of infection, the accumulation of ‘‘inﬂationary’’ IFN-g
1
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/ mice have elevated early but reduced persistent MCMV-speciﬁc CD8 responses. WT C57BL/6 (&) and 4-1BB-deﬁcient (&) mice
were infected with MCMVand on days 0, 7, 14 and 30 post-infection, CD8
1 cells speciﬁc for M45 (A), M57 (B), M38 (C) and m139 (D) were quantiﬁed
on the basis of intracellular IFN-g production (E and F). Numbers of peptide-speciﬁc CD8
1 cells 7 (E) and 30 (F) days post-infection. Results are
expressed as numbers of peptide-speciﬁc CD8
1 cells/spleen and are shown as mean7SEM of four mice/group, representing three independent
experiments. (G) Representative plots of M45-speciﬁc tetramer-binding CD44
1 CD8
1 T cells from WT (left) and 4-1BB
/ mice 7 days post-infection.
Results represent eight mice from two experiments. (H) Splenic M45-speciﬁc CD8
1 cell numbers 7 days after immunization with M45 peptide/CFA.
Mean7SEM of four mice/group is shown. (I) Numbers of peptide speciﬁc CD4
1 cells 7 days post-infection. Individual mice and mean values are
shown, and data represent two independent experiments. (J) In vivo CTL assay as described in the Materials and methods section. Representative
plots of loaded cells prior to transfer (top) and from MCMV-infected WT (middle) and 4-1BB
/ (bottom) mice 7 days post-infection are shown, and
represent four mice/group. (K) MCMV glycoprotein B content in genomic DNA from spleens of WTand 4-1BB
/ mice 7 and 30 days post-infection
was measured by qPCR and normalized to b-actin. Results are expressed as mean7SEM of three mice/group. (L) Infectious viral load in salivary
glands was measured by plaque assay. Individual mice and mean values are shown. (M) Representative plots of M38- and m139-speciﬁc tetramer-
binding CD8
1 T cells from WT (left) and 4-1BB
/ (right) mice 30 days post-infection. Results represent 12 mice from two independent
experiments. (N) Numbers of peptide speciﬁc CD4
1 T cells 30 days post-infection. Individual mice are shown and data represent two independent
experiments. Signiﬁcance is p o 0.05, Student’s t-test.
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1 T cells during the early phase of
latent/chronic infection (day 30) was reduced in the spleens of
4-1BB
/ mice compared with WT controls (Fig. 1C, D and F).
Similarly, M38-speciﬁc CD8
1 T-cell numbers were reduced in the
lungs of 4-1BB
/ mice at this time (data not shown). Moreover,
reduced frequencies of tetramer binding inﬂationary CD8
1 T cells
were observed in 4-1BB
/ mice (Fig. 1M), suggesting that 4-1BB
regulated the accumulation rather than function (IFN-g produc-
tion) of these memory cells. Virus load at 30 days was
comparable in spleens (Fig. 1K) and salivary glands (Fig. 1L) of
WT and 4-1BB
/ mice, suggesting that impaired T-cell inﬂation
in 4-1BB
/ mice was again not a consequence of reduced
antigen abundance. CD4
1 T cells contribute to the size of these
late CD8
1 T-cell populations [27, 28]. Surprisingly, however,
accumulation of virus-speciﬁc CD4
1 T cells was actually
enhanced in 4-1BB
/ mice (Fig. 1N), suggesting that impair-
ment of memory CD8
1 T-cell responses in these mice was not a
consequence of reduced CD4
1 T-cell help. Collectively, these data
show that 4-1BB has a biphasic action by limiting CD8
1 T-cell
priming during acute MCMV infection yet promoting inﬂationary
CD8
1 T-cell accumulation at later stages of infection.
4-1BBL does not contribute to 4-1BB-mediated
suppression of acute CD8
1 T-cell responses
We next investigated whether 4-1BBL played a role in these
divergent responses revealed in the absence of 4-1BB. Analyzing
B6 and 4-1BB
/ mice (in which surface expression of 4-1BBL is
stabilized [29]), we observed that 4-1BBL was expressed by
B220
1 and CD11b
1CD11c
1 cells during acute infection, although
it was more abundant at late times (day 7) rather than at early
times (Fig. 2A). Analysis of 4-1BB-deﬁcient mice at day 7, but not
at day 3, showed a much higher level of 4-1BBL expression than
in WT mice, implying that productive 4-1BB/4-1BBL interactions
(that can result in cleavage of surface 4-1BBL) were occurring
late but not early during initial infection. Correlating with this,
when acute CD8
1 T-cell responses were examined in 4-1BBL-
deﬁcient mice, we found no defect in the generation of any of
the MCMV-reactive populations compared with WT controls
(Fig. 2B). Furthermore, this result was replicated in WT mice
treated with a blocking antibody to 4-1BBL given during the ﬁrst
week of infection (Fig. 2C). These results show that the
suppressive activity of 4-1BB on acute CD8
1 T-cell responses
occurs independently of 4-1BBL.
4-1BBL promotes MCMV-speciﬁc memory CD8
1 T-cell
accumulation
Given that 4-1BBL promotes the generation of some anti-viral
memory CD8
1 T-cell populations in mice, and 4-1BBL binding to
4-1BB induces the expansion of human HCMV-speciﬁc CD8
1
memory T cells in vitro [30], we investigated whether 4-1BBL
might control the later accumulation of inﬂationary CD8
1 T cells.
Thirty days after infection, 4-1BBL
/ mice displayed reduced
accumulation of these persistent CD8
1 T-cell populations
(Fig. 3A), similar to the defect seen in 4-1BB
/ mice (Fig. 1F).
Furthermore, we found that treatment of WT mice with a
blocking a4-1BBL antibody given on days 0–5 (Fig. 3B), but not
days 7–13 (Fig. 3C), post-infection, also reduced the MCMV-
speciﬁc CD8
1 T-cell responses measured at 1 month, suggesting
that the requirement for and activity of 4-1BBL likely occurred
just before or at the peak of the effector T-cell response in the ﬁrst
week of infection, correlating with the expression data above. As
seen in 4-1BB
/ mice, impaired T-cell inﬂation following early
4-1BBL blockade was not associated with reduced MCMV genome
load in the spleen (data not shown). Some variability in T-cell
responses was seen between experimental groups, such that
Figure 2. 4-1BB-mediated suppression of early anti-viral CD8
1 T cells
is independent of 4-1BBL. (A) WTand 4-1BB
/ mice were infected with
MCMV and expression of 4-1BBL on B220
1 and CD11b
1CD11c
1 cells
was measured by ﬂow cytometry after 3 (left panels) and 7 (right
panels) days. Closed line, isotype; open line, a4-1BBL. (B) WT (&) and
4-1BBL
/ (&) mice were infected with MCMV and numbers of virus-
speciﬁc IFNg
1 CD8
1 cells were enumerated on day 7. (C) WT mice were
treated with IgG (&)o ra4-1BBL (&) on days 0, 2 and 5, and virus-
speciﬁc IFNg
1 CD8
1 cells were enumerated on day 7. All results shown
are mean numbers7SEM of four mice/group and represent two to
three independent experiments. p o 0.05, Student’s t-test.
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combining the 4-1BBL knockout and 4-1BBL-blocking studies
together essentially replicated the defective accumulation of both
M38 and m139-reactive CD8
1 T cells that were seen in the
absence of 4-1BB. Thus, acute MCMV-speciﬁc CD8
1 T-cell
responses are negatively regulated by 4-1BB, but independent
of 4-1BBL, whereas late CD8
1 T-cell responses are positively
regulated by 4-1BB and dependent on 4-1BBL.
As the inhibitory action of 4-1BB on acute CD8
1 T-cell
responses was proven to be independent of its interaction with
4-1BBL, this leads to several possible conclusions. First, 4-1BB
might function in an autonomous manner, irrespective of
engagement by a ligand, perhaps as part of another receptor
complex. Alternatively, and the explanation we favor, is that the
suppressive action of 4-1BB depends on the presence of another
as yet unidentiﬁed binding partner. We had previously hypothe-
sized the existence of such a partner based on the unusual hyper-
reactivity reported in 4-1BB
/ mice [23, 24] that had never been
observed in publications with 4-1BBL
/ mice. The direct
comparison here between the knockout strains represents the ﬁrst
instance where divergent activities have been seen in the same
model. Brieﬂy, 4-1BB binds several extra-cellular matrix proteins,
including laminin [31]. However, given the ubiquitous expression
of ECM proteins, it is unlikely that these will account for the
selective kinetics of 4-1BB suppression. Any novel interaction
with 4-1BB may operate in several ways. It may suppress CD8
1
T cells by inducing a negative signal through 4-1BB expressed on
the T cell. Alternatively, it might induce an inhibitory signal in the
T cell through the alternate ligand, following either cis- or trans-
interactions with 4-1BB expressed on a neighboring T cell or APC,
respectively. Another possibility is that 4-1BB stimulates an APC
or regulatory population, through 4-1BB or its alternate partner,
leading to expression of a suppressive molecule. Importantly, in
terms of viral immunity, 4-1BB-mediated inhibition of CD8
1
T-cell priming was not observed following M45 peptide immu-
nization, or in response to vaccinia virus (data not shown),
highlighting the activity of MCMV in eliciting this inhibitory
function. It is conceivable that MCMV expresses a 4-1BB-binding
protein that preferentially induces negative signaling. More
likely, MCMV may induce the expression of a host factor(s) that
upregulates a 4-1BB binding ligand. Irrespective, identifying any
novel ligands for 4-1BB, and understanding the mechanisms by
which they might promote 4-1BB-mediated suppression of T cells,
will be crucial for our understanding of how 4-1BB regulates anti-
MCMV immune responses.
Our further conclusions show that MCMV-speciﬁc CD8
1 T-cell
memory formation is promoted by 4-1BB/4-1BBL costimulatory
events that occur during acute infection when, paradoxically, 4-1BB
concurrently inhibits primary CD8
1 T-cell populations in a 4-1BBL-
independent manner. It is possible, however, that these events are
temporally distinct. One idea is that M45- and M57-speciﬁc popu-
lations expand quickly because the peptides are readily available,
but that M38- and m139-speciﬁc populations exhibit delayed
expansion kinetics of development as the peptides are either not
presented immediately or are less abundant. The suppressive
activity of 4-1BB might dominate early, resulting in diminished
responses to M45 and M57 responses, because 4-1BBL is not
expressed at high levels during the very early phase of infection. On
the contrary, at later times during the acute response, perhaps
coinciding with maximal M38 and m139 peptides presentation
enhanced levels of 4-1BBL might result, switching the activity of
4-1BB from being anti-inﬂammatory to pro-inﬂammatory and
hence aiding the generation of CD8
1 T cells to these epitopes.
Concluding remarks
Our data add to the signiﬁcance of the literature, showing that
human CD8
1 T cells recognizing peptides derived from inﬂuenza,
EBV [32] and HIV [33] can be promoted by providing 4-1BBL to
engage 4-1BB, and similarly that HCMV-speciﬁc effector memory
CD8
1 T cells can respond to 4-1BB signals [30]. However, the
observation that 4-1BB exerts differential effects on anti-viral
Figure 3. 4-1BB/4-1BBL interactions during acute infection promote
CD8 persistence. (A) WT (&) and 4-1BBL
/ (&) mice were infected
with MCMVand numbers of virus-speciﬁc CD8
1 cells were enumerated
functionally 30 days later. (B and C) MCMV-infected WT mice were
treated with IgG (&)o ra4-1BBL (&) antibody on days 0, 2 and 5 (B) or 7,
10 and 13 (C) and MCMV-speciﬁc CD8
1 cells were enumerated
functionally after 30 (B) or 28 (C) days. All results shown are mean
numbers7SEM of four to six mice/group and representative of two
independent experiments. p o 0.05, Student’s t-test.
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1 T-cell responses at varying stages of infection, and that
4-1BBL is dispensable for early suppression of CD8
1 cells,
underlines the complexity of the 4-1BB/4-1BBL pathway and
highlights the need for greater understanding before manipulat-
ing these molecules to promote anti-viral immunity in the clinic.
Materials and methods
Mice
C57BL/6 and C57BL/6
Pep3b/BoyJ (CD45.1
1) mice were purchased
from The Jackson Laboratory. 4-1BB
/ and 4-1BBL
/ mice
were originally provided by Byoung Kwon and Amgen, respec-
tively. All experiments were conducted following the guidelines
of the La Jolla Institute for Allergy and Immunology’s Institu-
tional Animal Care and Use Committee.
Virus, mouse infections and treatments
MCMV Smith strain (ATCC) was prepared, isolated and titred
from salivary glands as described previously [27]. Mice were
infected i.p. with 510
4pfu MCMV. In some experiments, mice
were also injected with 250mg rat IgG (Chemicon) or anti-4-1BBL
(clone 19h3, a kind gift from Robert Mittler) on days stated in the
ﬁgure legends. In other experiments, mice were immunized with
25mg peptide in 100mL CFA s.c. tail base.
Flow cytometry
Peptide-speciﬁc IFN-g-expressing CD8
1 T cells were measured as
described previously [29]. To examine tetramer-binding CD8
1
T cells, 110
6 splenocytes were incubated with Fc block and
then stained with M45/H-2D
b, M38/H-2K
b or m139/H-2K
b
tetramers. Cells were then stained with aCD3-PerCP-Cy5.5 (BD
Pharmingen) and aCD8-APC-H7 (BD Pharmingen).
To identify MCMV-speciﬁc CD4
1 T cells, splenocytes were
incubated for 5h at 371C with 2mg/mL brefeldin A (Sigma-
Aldrich) and 3mg/mL MHC class II restricted MCMV-derived
peptides (Genscript) derived from the M25, m139 and M142
proteins [34]. Cells were then incubated with Fc block and
surface stained with aCD4-Paciﬁc Blue (BD Pharmingen) prior to
permeabilization and intracellular staining with aIFN-g-FITC. All
data were acquired on an LSR II ﬂow cytometer (BD Bioscience)
and analyzed with FlowJo software.
In vivo CTL assay
CD45.1
1 splenocytes were loaded with M45 or OT-I (SINFEKL)
peptide (5mg/mL) for 60min and labeled with CFSE
lo (0.5mM)
and CFSE
hi (5mM), respectively. Five million CD45.1
1 target cells
(2.510
6 each) were adoptively transferred to MCMV-infected
WT and 4-1BB
/ mice 7 days after infection. Spleen cells were
isolated 3h after transfer and CD45.1
1CFSE
1 target cells were
quantiﬁed by ﬂow cytometry.
Viral genome detection
Genomic DNA was isolated from spleen and lung tissue using a
DNAeasy tissue kit (Qiagen). MCMV glycoprotein B was then
assayed by quantitative PCR using a Mini Opticon (Biorad
Laboratories) and Platinum SYBR green mastermix reagent (Invitro-
gen). In total, 100ng aliquots of DNA were used as templates for
each reaction. The primer sequences are available upon request.
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